Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.
about
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Systemic immune response induc ...... on in high-risk rectal cancer.
@en
Systemic immune response induc ...... on in high-risk rectal cancer.
@nl
type
label
Systemic immune response induc ...... on in high-risk rectal cancer.
@en
Systemic immune response induc ...... on in high-risk rectal cancer.
@nl
prefLabel
Systemic immune response induc ...... on in high-risk rectal cancer.
@en
Systemic immune response induc ...... on in high-risk rectal cancer.
@nl
P2093
P2860
P50
P1476
Systemic immune response induc ...... on in high-risk rectal cancer.
@en
P2093
Benny Vittrup Jensen
Dorte Lisbet Nielsen
Erta Kalanxhi
Finn Ole Larsen
Jakob Vasehus Schou
Knut Håkon Hole
Sebastian Meltzer
P2860
P2888
P304
P356
10.1038/S41416-018-0085-Y
P407
P577
2018-04-26T00:00:00Z